Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Shares of Amgen Inc. ($AMGN) edged down 0.3% in premarket trading Wednesday, on course to extend a losing streak to a third ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

The Phase 2 study showed people living with obesity or overweight ... unknowns around this drug's tolerability profile & titration schedule that we won't have more clarity on until next year at a ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

Joe Biden wants diabetes drugs that aid weight loss and treat obesity, such as Wegovy, to fall under Medicare and Medicaid.

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...